# Cannabis & Psychosis Study > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-psychosis-study-signal-or-overstatement/ > **Published:** 2026-05-14T23:36:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:07:19-04:00 > **Clinical Summary:** A physician-led review of a cannabis psychosis study examining cannabis and tobacco co-use, psychosis risk, subgroup findings, and major interpretive limitations. --- CED Clinical Relevance 7.8 / 10 • Important Signal With Significant Interpretive Limits Clinically meaningful observational findings in a highly vulnerable psychiatric population. This study raises legitimate concern around heavy cannabis exposure in people already at clinical high risk for psychosis, but the design and exposure limitations leave substantial uncertainty around causality and generalizability. Clinical Insight | CED Clinic The strongest finding in this paper came from a narrow subgroup inside a population already considered clinically high risk for psychosis. That distinction dramatically changes what the study can and cannot support clinically. [Psychosis Risk](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) Cannabis Tobacco Co-Use Clinical High Risk Overstated Harm Critique Audience Patients, caregivers, clinicians, psychiatry readers, policy audiences Primary Topic Cannabis and tobacco co-use in clinically high-risk psychosis cohorts Source Link [More access here](https://cedclinic.com/) ## Cannabis Psychosis Risk Study: A Concerning Signal, But Not A Simple Causal Story This prospective observational study followed people already identified as clinically high risk for psychosis and examined whether [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), tobacco use, or cannabis-tobacco co-use were associated with later conversion to psychosis. The paper identified a concerning subgroup signal involving heavy [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and light tobacco use, but several related analyses weakened after adjustment or failed to reach conventional statistical significance, reinforcing that this is an important association study rather than definitive proof of causation. ## What This Cannabis Psychosis Risk Study Teaches Us This paper examined 734 individuals already classified as clinically high risk for psychosis and evaluated whether baseline cannabis use, tobacco use, or cannabis-tobacco co-use predicted later conversion to psychosis over approximately two years. The most attention-grabbing finding involved a subgroup reporting heavy cannabis use combined with light tobacco use, which showed higher observed conversion risk than people reporting no cannabis or tobacco exposure. But several related analyses weakened after adjustment, some findings became statistically borderline, and the study relied on broad self-reported exposure categories without cannabinoid composition, potency, route, or cumulative-dose detail. The most clinically responsible interpretation is that heavier cannabis exposure may identify increased vulnerability within already high-risk psychiatric populations, not that the study proved cannabis exposure independently caused psychosis. ## Why This Matters For Patients and Families Many public headlines will compress this paper into phrases like “cannabis causes psychosis.” That is not what the study measured. The participants were already considered clinically high risk before substance-use analyses occurred, which makes these findings much more specific and context-dependent than broad public narratives often imply. For Clinicians The findings support thoughtful screening and counseling around heavy THC exposure in vulnerable psychiatric populations. But they also reinforce how difficult it remains to disentangle cannabis exposure from trauma, developmental instability, shared genetics, psychiatric severity, polysubstance use, and other overlapping vulnerability factors. For Policy and Research Readers This paper illustrates how observational psychiatric research can become distorted once it enters public discourse. The study raises legitimate concern, but it also contains major exposure-definition, subgroup, and confounding limitations that deserve equal visibility alongside the headline findings. ## Study Snapshot Study Type Prospective observational longitudinal cohort study Population 734 individuals at clinical high risk for psychosis and 278 healthy controls across eight North American sites Exposure Baseline past-30-day self-reported cannabis and tobacco use frequency Comparator No cannabis/no tobacco use and multiple substance-use subgroup comparisons Primary Outcomes Conversion to psychosis and psychiatric symptom severity Follow-Up Assessments every six months over approximately two years Journal Nature Mental Health Year 2026 DOI 10.1038/s44220-026-00648-y Funding / Conflicts NIH-supported study; authors declared no competing interests visible in the paper. ## Clinical Bottom Line This study supports careful counseling around frequent THC exposure in individuals already showing psychosis vulnerability. But the findings remain observational, subgroup-sensitive, and heavily limited by broad exposure definitions, meaning they should not be interpreted as proof that cannabis exposure alone causes psychosis broadly across populations. ## What This Paper Looked At The investigators used data from the North American Prodrome Longitudinal Study-2 (NAPLS2), a large multicenter cohort following individuals identified as clinically high risk for psychosis. Participants completed baseline substance-use assessments and longitudinal psychiatric follow-up over approximately two years. The study evaluated whether baseline cannabis use, tobacco use, or cannabis-tobacco co-use patterns were associated with later conversion to psychosis. Exposure was measured using broad self-reported frequency categories over the prior 30 days. Participants were grouped into cannabis-only, tobacco-only, cannabis-plus-tobacco co-use, other-substance-use, and no-substance-use categories, with additional light-versus-heavy exposure subgroup analyses. This was not a randomized trial. Researchers observed naturally occurring substance-use patterns within an already vulnerable psychiatric population. ## What the Paper Found Higher cannabis-use frequency showed an association with higher conversion risk in one age- and sex-adjusted Cox model. But when cannabis use was modeled while controlling for tobacco exposure, the association weakened and no longer reached conventional statistical significance. Categorical cannabis-tobacco co-use also failed to reach conventional statistical significance in one analysis. The subgroup producing the strongest signal involved heavy cannabis use combined with light tobacco use, which showed elevated conversion risk relative to no cannabis/no tobacco exposure. One nuance that deserves more attention is that the strongest signal did *not* emerge in the heavy cannabis/heavy tobacco subgroup. Instead, it appeared in the heavy cannabis/light tobacco subgroup. That complicates any simplistic interpretation that “more tobacco plus more cannabis equals more psychosis risk,” and raises the possibility of subgroup instability, interaction effects, vulnerability clustering, or chance findings that require replication. Another important finding received much less public attention: the different clinical-high-risk substance-use groups did not significantly differ in baseline psychosis symptom severity. ## How Strong Is This Evidence This is a meaningful prospective cohort study published in a high-impact journal using a relatively large multicenter sample. The longitudinal design is stronger than purely cross-sectional association studies because it followed participants over time before conversion outcomes occurred. But the study still remains observational, which means it cannot fully separate cannabis exposure from shared vulnerability factors such as trauma, psychiatric severity, genetics, social adversity, impulsivity, developmental instability, or other substance use. The exposure definition was also remarkably broad. “Cannabis use” in this paper included highly heterogeneous real-world exposures compressed into self-reported frequency categories without THC potency, CBD content, route, product type, cumulative dose, or simultaneous-versus-asynchronous tobacco-use detail. The study also relied on baseline past-30-day self-reported exposure categories collected between 2009 and 2013. That predates much of the modern retail cannabis market, including widespread concentrates, contemporary vaping patterns, and many high-potency commercial products. Another important limitation is that subgroup findings are statistically vulnerable to instability. The strongest signal emerged in a narrower intensity-defined subgroup rather than consistently across all co-use models. ## Where This Paper Deserves Skepticism **The population was already highly vulnerable.** These participants were not representative of the general population. They were already classified as clinically high risk for psychosis before substance-use analyses occurred. **The exposure definition was crude.** The study could not distinguish THC potency, cannabinoid composition, route, cumulative dose, developmental timing, or simultaneous versus asynchronous co-use. **The broader co-use finding was weaker than many headlines will imply.** The categorical cannabis-tobacco co-use model itself did not reach conventional statistical significance. The strongest signal emerged only after dividing participants into narrower intensity-defined subgroups. **Residual confounding remains substantial.** Shared vulnerability factors such as trauma exposure, family history, psychiatric burden, developmental instability, and social adversity could plausibly explain part of the observed associations. **E-values do not eliminate the main uncertainty problems here.** E-values address one dimension of unmeasured confounding, but they do not protect against subgroup instability, exposure misclassification, sparse-event amplification, or analytic multiplicity. **The findings come from an older cannabis-exposure era.** Data collection occurred before many contemporary retail cannabis products and modern vaping behaviors became widespread. ## What This Paper Does Not Show This paper does not prove that cannabis causes psychosis. It does not establish that all cannabis products carry equal [psychiatric risk](https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/). It does not determine whether cannabis use functioned as a causal exposure, a coping mechanism, a marker of psychiatric vulnerability, or some combination of those possibilities. It does not establish that most cannabis users face major psychosis risk. It does not provide product-specific guidance regarding THC potency, CBD ratios, [inhalation methods](https://cedclinic.com/respiratory-effects-inhalational-marijuana/), or safer-use thresholds. It does not isolate cannabis exposure from trauma, genetics, social adversity, psychiatric severity, or polysubstance use. And it does not justify broad public narratives claiming cannabis exposure alone explains psychotic illness across populations. ## How This Fits With the Broader Clinical Conversation The broader cannabis-psychosis literature has repeatedly identified concerning association signals, especially around heavier cannabis exposure, earlier onset, relapse risk, and vulnerable psychiatric populations. But one reason the literature remains debated is that observational studies continue struggling to disentangle cannabis exposure from genetics, developmental instability, trauma burden, social adversity, psychiatric severity, and other overlapping vulnerability structures. This paper fits within that broader pattern. It reinforces that concern around heavy THC exposure in vulnerable populations is reasonable, while also reinforcing how difficult it remains to identify a clean independent causal effect. The study is therefore best understood as an incremental and hypothesis-generating contribution rather than a definitive settlement of the cannabis-psychosis debate. ## Dr. Caplan’s Take *What catches my attention most here is not simply the association signal itself, but how easily a paper like this can become flattened into a simplistic cultural headline. The study identified a meaningful risk signal inside a very vulnerable psychiatric population. That deserves serious attention. But it is still very different from proving cannabis broadly causes psychosis.* *The part I would be careful with is the exposure definition. “Cannabis use” in this paper includes highly heterogeneous real-world exposures compressed into broad self-reported frequency categories. Clinically, THC potency, CBD composition, developmental timing, route of administration, and reason for use may matter enormously.* *One of the most important humility points in this paper is that the participants were already considered clinically high risk before cannabis exposure entered the analysis. That makes this a vulnerability-framing study more than a population-wide causation study. In practice, I think that distinction gets lost constantly once papers like this become headlines.* *At the same time, I would not dismiss the findings entirely. In real clinical care, I do think heavy THC exposure deserves thoughtful caution in people with prodromal symptoms, paranoia, strong family history, severe dissociation, or unstable psychiatric trajectories. But this paper should be read as an important observational signal, not a deterministic causal map.* ## What a Careful Reader Should Take Away The fairest reading of this paper is that heavier cannabis exposure, particularly within certain tobacco co-use patterns, may identify increased conversion vulnerability in people already at clinical high risk for psychosis. That is clinically meaningful. But the findings remain observational, subgroup-sensitive, historically limited, and unable to cleanly resolve whether cannabis exposure itself independently caused psychosis conversion. ## Join the Conversation How should clinicians and the public talk about psychiatric [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) without drifting into either alarmism or dismissal? What kinds of nuance do you think get lost most often in headlines like these? Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis%20Psychosis%20Study%3A%20A%20Concerning%20Signal%2C%20But%20Not%20A%20Simple%20Causal%20Story&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-psychosis-study-signal-or-overstatement%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-psychosis-study-signal-or-overstatement%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis%20Psychosis%20Study%3A%20A%20Concerning%20Signal%2C%20But%20Not%20A%20Simple%20Causal%20Story%20https%3A%2F%2Fcedclinic.com%2Fcannabis-psychosis-study-signal-or-overstatement%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source Bello D, Blyth SH, Rabin RA, et al. *Cannabis and tobacco co-use predicts psychosis in clinical high risk cohorts.* Nature Mental Health. 2026. DOI: 10.1038/s44220-026-00648-y. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ## FAQ Did this study prove cannabis causes psychosis? No. This was an observational cohort study in a clinically high-risk psychiatric population. It identified associations, not definitive causation. Who was actually studied? Individuals already identified as clinically high risk for psychosis before substance-use analyses occurred. Why does the “heavy cannabis plus light tobacco” finding matter? Because the strongest signal emerged in a narrower subgroup rather than consistently across all co-use models, suggesting the relationship may be more complicated than a simple dose-dependent tobacco effect. Did this study reflect today’s cannabis products? Not completely. Data were collected between 2009 and 2013, before many modern concentrates, vaping products, and high-potency commercial cannabis products became widespread. Did the study measure THC potency or CBD content? No. The paper used broad self-reported frequency categories and lacked detailed cannabinoid composition data. Could trauma, genetics, or psychiatric vulnerability explain part of the findings? Possibly. Residual confounding remains one of the biggest limitations in observational psychosis-risk research. What is the fairest clinical takeaway? Heavy THC exposure may deserve additional caution in people already showing psychosis vulnerability, but this paper should not be interpreted as deterministic proof that cannabis exposure alone causes psychotic illness. Did cannabis or tobacco users start out with worse psychosis symptoms? No significant difference was found. Within the clinical high-risk cohort, the different substance-use groups did not significantly differ in baseline psychosis symptom severity. The article points out that this finding received much less public attention than the headline results on later conversion to psychosis.   ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).